CAR T Cell Therapy’s Potential for Pediatric Brain Tumors

Malignant central nervous system tumors are the leading cause of cancer death in children. Progress in high-throughput molecular techniques has increased the molecular understanding of these tumors, but the outcomes are still poor. Even when efficacious, surgery, radiation, and chemotherapy cause ne...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pauline Thomas, Natacha Galopin, Emma Bonérandi, Béatrice Clémenceau, Sophie Fougeray, Stéphane Birklé
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chimeric antigen receptor T cell medulloblastoma atypical teratoid rhabdoid tumors ependymoma high-grade glioma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ae313db6a6094e169834075363a59a1f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae313db6a6094e169834075363a59a1f
record_format	dspace
spelling	oai:doaj.org-article:ae313db6a6094e169834075363a59a1f2021-11-11T15:32:33ZCAR T Cell Therapy’s Potential for Pediatric Brain Tumors10.3390/cancers132154452072-6694https://doaj.org/article/ae313db6a6094e169834075363a59a1f2021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5445https://doaj.org/toc/2072-6694Malignant central nervous system tumors are the leading cause of cancer death in children. Progress in high-throughput molecular techniques has increased the molecular understanding of these tumors, but the outcomes are still poor. Even when efficacious, surgery, radiation, and chemotherapy cause neurologic and neurocognitive morbidity. Adoptive cell therapy with autologous CD19 chimeric antigen receptor T cells (CAR T) has demonstrated remarkable remission rates in patients with relapsed refractory B cell malignancies. Unfortunately, tumor heterogeneity, the identification of appropriate target antigens, and location in a growing brain behind the blood–brain barrier within a specific suppressive immune microenvironment restrict the efficacy of this strategy in pediatric neuro-oncology. In addition, the vulnerability of the brain to unrepairable tissue damage raises important safety concerns. Recent preclinical findings, however, have provided a strong rationale for clinical trials of this approach in patients. Here, we examine the most important challenges associated with the development of CAR T cell immunotherapy and further present the latest preclinical strategies intending to optimize genetically engineered T cells’ efficiency and safety in the field of pediatric neuro-oncology.Pauline ThomasNatacha GalopinEmma BonérandiBéatrice ClémenceauSophie FougerayStéphane BirkléMDPI AGarticlechimeric antigen receptorT cellmedulloblastomaatypical teratoid rhabdoid tumorsependymomahigh-grade gliomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5445, p 5445 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chimeric antigen receptor T cell medulloblastoma atypical teratoid rhabdoid tumors ependymoma high-grade glioma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chimeric antigen receptor T cell medulloblastoma atypical teratoid rhabdoid tumors ependymoma high-grade glioma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Pauline Thomas Natacha Galopin Emma Bonérandi Béatrice Clémenceau Sophie Fougeray Stéphane Birklé CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
description	Malignant central nervous system tumors are the leading cause of cancer death in children. Progress in high-throughput molecular techniques has increased the molecular understanding of these tumors, but the outcomes are still poor. Even when efficacious, surgery, radiation, and chemotherapy cause neurologic and neurocognitive morbidity. Adoptive cell therapy with autologous CD19 chimeric antigen receptor T cells (CAR T) has demonstrated remarkable remission rates in patients with relapsed refractory B cell malignancies. Unfortunately, tumor heterogeneity, the identification of appropriate target antigens, and location in a growing brain behind the blood–brain barrier within a specific suppressive immune microenvironment restrict the efficacy of this strategy in pediatric neuro-oncology. In addition, the vulnerability of the brain to unrepairable tissue damage raises important safety concerns. Recent preclinical findings, however, have provided a strong rationale for clinical trials of this approach in patients. Here, we examine the most important challenges associated with the development of CAR T cell immunotherapy and further present the latest preclinical strategies intending to optimize genetically engineered T cells’ efficiency and safety in the field of pediatric neuro-oncology.
format	article
author	Pauline Thomas Natacha Galopin Emma Bonérandi Béatrice Clémenceau Sophie Fougeray Stéphane Birklé
author_facet	Pauline Thomas Natacha Galopin Emma Bonérandi Béatrice Clémenceau Sophie Fougeray Stéphane Birklé
author_sort	Pauline Thomas
title	CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
title_short	CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
title_full	CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
title_fullStr	CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
title_full_unstemmed	CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
title_sort	car t cell therapy’s potential for pediatric brain tumors
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ae313db6a6094e169834075363a59a1f
work_keys_str_mv	AT paulinethomas cartcelltherapyspotentialforpediatricbraintumors AT natachagalopin cartcelltherapyspotentialforpediatricbraintumors AT emmabonerandi cartcelltherapyspotentialforpediatricbraintumors AT beatriceclemenceau cartcelltherapyspotentialforpediatricbraintumors AT sophiefougeray cartcelltherapyspotentialforpediatricbraintumors AT stephanebirkle cartcelltherapyspotentialforpediatricbraintumors
_version_	1718435261244768256

CAR T Cell Therapy’s Potential for Pediatric Brain Tumors

Ejemplares similares